This could be due to different experimental systems, such as cell line versus xenograft models, different cancer type, different cancer drivers, etc. Here, our Myc/xmrk transgenic zebrafish provide a context-specific, tumor-specific and pathway-specific in vivo model to address these questions. This evidence concerns the gene MYC and cancer.